Catch up on a few of the top stories from Modern Retina in 2023.

Much has changed in the study of keratoconus over the years.

A report by Technavio indicates that lifestyle changes will increase eyewear sales across the globe.

A look back at some of the biggest stories in ophthalmology in 2023.

Larger 0.6-mm temporary plug features a tapered edge.

From FDA approvals to innovations in lens tech, 2023 was a big year in eye care.

Catch up on what happened in optometry during the week of December 18-December 22.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

Damon Dierker, OD, FAAO, shares latest updates in research on sutureless cryopreserved amniotic membrane for moderate-to-severe dry eye with short treatment duration.

Although the differential diagnosis of pigmented fundus lesions is limited, the distinctions among these lesions are not always clear.

Catch up on what happened in optometry during the week of December 11-December 15.

Eye care witnessed a transformative year with 11 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.

iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.

OCU410 is a modifier gene therapy product candidate being developed by Ocugen for dry AMD.

The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

A research report compiled by The Vision Council reveals that most parents are aware of myopia but remain in the dark about prevalence and how to prevent progression.

Etiology is crucial to substantive treatment.

Rapid macular thinning often precedes traditional symptoms.

TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.